#1 Clinical Trials Search in Europe

Ertugliflozin

Ertugliflozin is a medication being studied for its effects on type 2 diabetes and heart conditions. Clinical trials are investigating how it impacts blood sugar levels, heart function, and other health measures in different patient groups. This article summarizes key findings from recent ertugliflozin clinical trials.

Table of Contents

What is Ertugliflozin?

Ertugliflozin is a medication used primarily for the treatment of type 2 diabetes mellitus. It is also known by the brand name Steglatro and may be referred to by its research codes PF-04971729 or MK-8835[1][2]. Ertugliflozin belongs to a class of drugs called sodium-glucose co-transporter-2 (SGLT2) inhibitors[3].

How Does Ertugliflozin Work?

Ertugliflozin works by blocking the action of a protein in your kidneys called SGLT2. This protein normally helps your body reabsorb glucose (sugar) from your urine back into your bloodstream. By inhibiting SGLT2, ertugliflozin causes more glucose to be excreted in your urine, which helps lower blood sugar levels[4].

This mechanism of action not only helps control blood sugar but also has some additional effects that researchers are studying. These include potential benefits for heart health and body weight[3].

What Conditions Does Ertugliflozin Treat?

Ertugliflozin is primarily used to treat:

  • Type 2 Diabetes Mellitus: This is the main condition for which ertugliflozin is prescribed. It helps control blood sugar levels in adults with type 2 diabetes[1].
  • Heart Failure: Recent research suggests that ertugliflozin may also be beneficial for patients with heart failure, particularly those with reduced ejection fraction (HFrEF). This is a condition where the heart muscle doesn’t pump blood as well as it should[5].
  • Cardiovascular Disease: Studies are investigating the potential benefits of ertugliflozin in reducing the risk of cardiovascular events in patients with type 2 diabetes who also have cardiovascular disease[6].

Dosage and Administration

Ertugliflozin is typically taken orally (by mouth) once daily. The usual starting dose is 5 mg, but this can vary depending on the individual patient and their condition. In some studies, doses up to 15 mg per day have been used[6][5].

It’s important to take ertugliflozin exactly as prescribed by your doctor. The medication can be taken with or without food. If you’re also taking insulin or medications that increase insulin production, your doctor may adjust these doses to reduce the risk of low blood sugar[4].

Potential Side Effects

Like all medications, ertugliflozin can cause side effects. Common side effects may include:

  • Increased urination
  • Thirst
  • Genital yeast infections
  • Urinary tract infections
  • Changes in blood lipid levels

More serious side effects, though rare, can include diabetic ketoacidosis (a dangerous condition where the body produces high levels of blood acids called ketones) and kidney problems. It’s important to discuss all potential side effects with your healthcare provider[7].

Ongoing Research and Potential New Uses

Researchers are currently studying ertugliflozin for several potential new uses:

  • Heart Failure Treatment: Studies are investigating how ertugliflozin affects heart function in patients with heart failure. This includes looking at its effects on the heart’s ability to pump blood effectively and on fluid retention in the body[5].
  • Mitral Valve Regurgitation: This is a condition where the heart’s mitral valve doesn’t close properly, allowing blood to flow backward in the heart. A study is examining whether ertugliflozin can help reduce the severity of this condition[8].
  • Effects on Body Fat: Researchers are studying how ertugliflozin affects different types of body fat, including fat around the heart (epicardial fat). This could provide insights into how the drug affects cardiovascular health[6].
  • Cardiac Fibrosis: This refers to the formation of scar tissue in the heart. A study is looking at whether ertugliflozin can help reduce cardiac fibrosis in patients with heart failure[3].

These ongoing studies may lead to new approved uses for ertugliflozin in the future, potentially benefiting a wider range of patients.

Aspect Details
Primary Conditions Studied Type 2 Diabetes Mellitus, Heart Failure, Left Ventricular Dysfunction
Key Dosages Ranging from 1 mg to 25 mg daily, with some studies testing up to 100 mg
Main Outcome Measures Blood glucose control, heart function parameters, kidney function, body weight
Imaging Techniques Used Cardiac MRI, Echocardiography
Notable Biomarkers NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Study Designs Randomized controlled trials, dose-escalation studies, pharmacokinetic studies
Patient Populations Diabetic patients, heart failure patients, healthy volunteers
Unique Applications Potential effects on cardiac fibrosis, mitral regurgitation
Safety Assessments Adverse event monitoring, tolerability evaluations
Duration of Studies Ranging from single-dose studies to 48-week trials

FAQ

  • What is ertugliflozin? Ertugliflozin is a medication that belongs to a class of drugs called SGLT2 inhibitors. It works by helping the kidneys remove excess sugar from the body through urine. It is being studied for treating type 2 diabetes and potentially providing benefits for heart health.
  • What conditions is ertugliflozin being studied for? Ertugliflozin is primarily being studied for type 2 diabetes management. However, clinical trials are also exploring its potential benefits for heart conditions like heart failure, left ventricular dysfunction, and mitral valve insufficiency.
  • How is ertugliflozin administered in clinical trials? In most clinical trials, ertugliflozin is given as an oral tablet, with doses typically ranging from 1 mg to 25 mg taken once daily. Some studies compare different doses or test it against a placebo.
  • What are some of the outcomes being measured in ertugliflozin trials? Trials are measuring various outcomes including blood sugar control, heart function (through measures like ejection fraction and cardiac imaging), kidney function, body weight changes, and biomarkers related to heart health. Safety and tolerability are also key focuses.
  • Are there any notable side effects of ertugliflozin observed in trials? While specific side effects aren't detailed in the trial summaries provided, SGLT2 inhibitors like ertugliflozin can potentially cause increased urination, urinary tract infections, and changes in blood electrolyte levels. Each trial closely monitors for adverse events to assess safety.

Ongoing Clinical Trials on Ertugliflozin

  • Study on the Effects of Ertugliflozin and Semaglutide on Heart Health in Patients with Type 2 Diabetes

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Romania

  • Study on the Effects of Ertugliflozin and Sodium Intake on Blood Pressure in Overweight Adults with Type 2 Diabetes

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Ertugliflozin for Children and Teens with Type 2 Diabetes

    Not recruiting

    3 1
    Investigated drugs:
    Hungary Italy Poland

Glossary

  • SGLT2 inhibitor: A class of medications that work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in urine and lowered blood sugar levels.
  • Type 2 Diabetes Mellitus (T2DM): A chronic condition characterized by high blood sugar levels due to the body's inability to effectively use insulin or produce enough insulin.
  • Heart Failure: A condition where the heart cannot pump blood effectively to meet the body's needs, often leading to symptoms like shortness of breath and fatigue.
  • Ejection Fraction: A measurement of how much blood the left ventricle pumps out with each contraction, used to assess heart function.
  • Mitral Regurgitation: A condition where the mitral valve in the heart doesn't close properly, allowing blood to flow backward in the heart.
  • Cardiac MRI: A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the heart's structure and function.
  • Biomarker: A measurable indicator of a biological state or condition, often used to assess disease progression or treatment effects.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the drug being studied.
  • Randomized Controlled Trial: A type of scientific experiment where participants are randomly allocated to receive either the treatment being studied or a placebo/standard treatment, used to minimize bias in research.
  • Left Ventricular Remodeling: Changes in the size, shape, and function of the left ventricle of the heart, often occurring in response to heart disease or injury.
  • NT-proBNP: A hormone released by the heart in response to changes in pressure inside the heart, used as a marker for heart failure.
  • Extracellular Volume (ECV): A measure of the space outside of cells in the body, used in cardiac imaging to assess tissue characteristics and fibrosis.

References

  1. https://clinicaltrials.gov/study/NCT01018823
  2. https://clinicaltrials.gov/study/NCT01223339
  3. https://clinicaltrials.gov/study/NCT04490681
  4. https://clinicaltrials.gov/study/NCT00989079
  5. https://clinicaltrials.gov/study/NCT05152940
  6. https://clinicaltrials.gov/study/NCT04167761
  7. https://clinicaltrials.gov/study/NCT01948986
  8. https://clinicaltrials.gov/study/NCT04231331